Ibogaine for Gambling Addiction: What Evidence Shows

Gambling disorder is the only behavioural addiction currently classified alongside substance use disorders in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR). Diagnosis requires four or more of nine criteria within a 12-month period — including escalating stakes, restlessness when cutting down, repeated failed attempts to stop, preoccupation, chasing losses, concealment, and jeopardising relationships or work.

That placement was deliberate. Gambling disorder shows the tolerance, craving, and loss-of-control patterns that define substance dependence — without any ingested drug.

Scale. The National Council on Problem Gambling estimates that about 2.5 million U.S. adults (roughly 1%) meet criteria for a severe gambling problem in a given year, with another 5–8 million (2–3%) experiencing mild or moderate problems. Legalised gambling now operates in 48 states plus the District of Columbia — every state except Hawaii and Utah. NCPG puts the annual national social cost at $14 billion, spanning criminal justice and healthcare spending, job loss, and bankruptcy.

The sports betting shift. After the Supreme Court's 2018 decision in Murphy v. NCAA, legal sportsbooks spread rapidly. A 2025 time-series study in JAMA Internal Medicine found that total sports wagers rose from $4.9 billion in 2017 to $121.1 billion in 2023 — with 94% placed online — and that internet searches for gambling-addiction help rose 23% nationally after Murphy.

Comorbidity is the rule, not the exception. A 2025 systematic review and meta-analysis in European Psychiatry pooling 12 population-based surveys found that 82.2% of people with gambling disorder had at least one mental disorder — roughly 10.7-fold elevated odds versus the general population. Substance use disorders were present in 34.2%, mood disorders 30.9%, anxiety disorders 29.9%, and bipolar or manic episodes 18.6%.

Suicide risk is substantial: a 2023 meta-analysis in the Journal of Gambling Studies reported lifetime pooled prevalences of 31% for suicidal ideation and 16% for suicide attempts.

These figures are not background detail — several bear directly on whether ibogaine could be considered at all.

Any experimental option must be measured against what already exists. For gambling disorder that comparison is nuanced — the psychotherapy evidence is real but its durability is genuinely uncertain, and no medication is approved for this indication anywhere in the world.

Psychological therapy is first-line.

• The 2012 Cochrane review (Cowlishaw and colleagues) of 14 randomised trials found that cognitive behavioural therapy produced clear benefits in the period immediately following treatment
• Its central caveat still stands: few studies extended to 12 months or beyond, so little is known about whether CBT effects last. Evidence quality was rated low to very low
• A 2026 review in American Family Physician puts it plainly: psychotherapy including CBT and motivational interviewing offers short-term benefit, while long-term effectiveness remains uncertain

Medication is off-label and modest. A 2026 critical review in Frontiers in Pharmacology (Bissig and Mutschler) examined roughly 22 agents — SSRIs, opioid antagonists, mood stabilisers, antipsychotics — and identified opioid antagonists as the most promising class, while noting that few studies, inconsistent designs, and contradictory results limit clinical applicability.

• A systematic review and network meta-analysis reported nalmefene as best-supported (standardised mean difference approximately −0.87 versus placebo), followed by naltrexone (approximately −0.43)
• Both produced significantly higher dropout from side effects than placebo
• Individual trials have been inconsistent — in at least one randomised comparison, naltrexone and placebo groups both improved substantially with no significant difference, a reminder that gambling behaviour often declines simply on entering a study

Other components of standard care:

• Gamblers Anonymous and mutual-help groups — limited formal evidence, but valuable structure and support
• Self-exclusion programmes and operator-level blocking tools
• Financial counselling and debt management, addressing a major driver of crisis and suicide risk
• Treatment of comorbid depression, anxiety, ADHD, and substance use disorders, often where the largest functional gains come from
• Screening in primary care with brief instruments such as the Lie/Bet questions; the disorder remains substantially underdiagnosed

The honest summary: treatments with randomised evidence exist, they help meaningfully in the short term, and relapse is common. Real unmet need remains — which is why unproven options attract attention, but unmet need is not itself evidence.

Ibogaine is a psychoactive indole alkaloid from the root bark of Tabernanthe iboga, studied almost exclusively as an experimental intervention for substance use disorders. Interest in ibogaine for gambling addiction does not come from clinical results. It comes from a chain of reasoning: gambling disorder sits in the addictions chapter of DSM-5 because it shares features with substance dependence; ibogaine's proposed anti-addictive action is not drug-specific but is described as acting on reward and craving circuitry broadly; therefore, the argument goes, it might apply to a behavioural addiction.

Ibogaine's pharmacology is unusually promiscuous. It acts as an NMDA receptor antagonist, a putative kappa-opioid agonist, a weak mu-opioid antagonist, and an antagonist at α3β4 nicotinic acetylcholine receptors — the target most consistently implicated in reduced drug self-administration in rodents. It also binds sigma-2 receptors and the serotonin transporter, and is metabolised largely by CYP2D6 to noribogaine, a long-lived active metabolite.

A separate mechanism receives most attention: ibogaine increases expression of glial cell line-derived neurotrophic factor (GDNF) in dopaminergic brain regions, an effect reported to be self-sustaining (He and Ron, FASEB Journal, 2006) and replicated in rats by Marton and colleagues in 2019.

A 2025 hypothesis paper in Frontiers in Pharmacology by Mark Nicolas articulates the transdiagnostic version of this argument, proposing ibogaine's neurotrophic and receptor-modulating properties as a mechanism for reward system recovery across diagnostic boundaries. Two points matter. First, it is explicitly labelled a "Hypothesis and Theory" article, not original research; the author states the framework "requires empirical validation." Second, the conditions it discusses are substance addiction, OCD, PTSD, and eating disorders — it does not present evidence for gambling disorder.

Where the reasoning weakens. Gambling disorder is not simply substance addiction without the substance. An integrative review in Molecular Psychiatry found that PET studies indicate amplified dopamine release in gambling disorder alongside minimal differences in baseline D2 receptor binding — a profile the authors describe as distinct from substance use disorders, where dopamine responses are typically blunted. Structural imaging shows only modest grey-matter changes, contrasting with clearer deterioration in SUD.

If gambling disorder involves an over-responsive rather than depleted dopaminergic system, a compound whose headline mechanism is dopaminergic neurotrophic upregulation is not obviously the right tool — and might not be neutral.

This is the shortest section on this page, because there is very little to report.

As of this writing, we could identify no published clinical study, case series, or case report of ibogaine used to treat gambling disorder in the peer-reviewed literature. Not a randomised trial, not an observational cohort, not a single documented case. There is also no published animal work applying ibogaine to a gambling-relevant behavioural model.

That is the evidence level: absent, not merely weak.

What does exist is adjacent. The human ibogaine literature is built on substance use disorder:

• Noller and colleagues (2018), a 12-month observational follow-up in New Zealand, reported reduced opioid withdrawal and craving and sustained reduction or cessation of opioid use in a subset of participants
• Brown and Alper (2018) and Mash and colleagues (2018) reported similar signals in Mexican clinic cohorts, the latter across 191 opioid- and cocaine-dependent patients
• A systematic review of human ibogaine studies identified 24 studies covering roughly 705 individuals — predominantly open-label studies, case series, and case reports, with very few controlled trials

Every one studied substances. None examined a behavioural addiction. Extrapolating from opioid detoxification — where much of ibogaine's observed effect is interruption of physical withdrawal, which gambling disorder does not involve — to compulsive gambling is a substantial and untested leap.

The psychedelic literature on gambling is also thin. A 2025 scoping review in Current Addiction Reports identified only a small body of gambling-relevant records — reported as one clinical trial, one observational study, four case studies, and sixteen literature reviews — with ketamine, LSD, and psilocybin the substances represented, not ibogaine. Imperial College London's Centre for Psychedelic Research has described an early-stage psilocybin study in gambling disorder; no results have been published.

What about clinic claims? A number of providers advertise ibogaine for gambling and other behavioural addictions, citing mechanistic reasoning and testimonials. Marketing claims are not evidence. No clinic has published gambling outcomes in a peer-reviewed venue, and no registered ibogaine trial lists gambling disorder as an indication.

Anyone told that ibogaine has been "shown to work" for gambling addiction should ask to see the study. There isn't one.

Because ibogaine is Schedule I in the United States, people seeking it travel to clinics in jurisdictions where it is unscheduled or tolerated — most commonly Mexico, and also Costa Rica and Portugal. Oversight varies enormously between providers, and no programme anywhere is an approved gambling disorder treatment.

A responsibly run programme should include, at minimum:

• 12-lead ECG with QTc measurement, and cardiology clearance for any abnormality
• Comprehensive metabolic panel including serum potassium and magnesium, corrected to normal range before dosing
• Liver and renal function testing and full blood count
• Medication and supplement reconciliation, screening for QT-prolonging and serotonergic agents
• Psychiatric history, specifically screening for bipolar disorder and psychosis
• CYP2D6 genotyping where available, to identify poor metabolisers with prolonged noribogaine exposure
• Continuous cardiac monitoring during and after dosing, with emergency response capability on site

The acute experience involves several hours of intense psychoactive effects followed by extended recovery with profound ataxia, nausea, vomiting, and inability to stand or walk unassisted for many hours. Sleep disruption commonly persists for days.

One timing caveat deserves emphasis: noribogaine's half-life is long, QT prolongation commonly persists beyond 24 hours, and documented adverse cardiac events have occurred 12 to 76 hours after dosing. Monitoring windows shorter than the pharmacokinetics warrant are a recognised weak point in some programmes.

Cost. Clinic-published pricing generally falls in the low- to mid-five-figure range, varying with programme length and monitoring level. These figures come from provider marketing and are not independently audited. No insurer covers ibogaine — and for a person whose presenting problem is gambling-related financial harm, spending five figures on an unproven intervention is itself a clinical risk factor, not a neutral decision.

Ibogaine's safety profile is dominated by cardiac electrophysiology, and gambling disorder adds a second layer of psychiatric concern.

The cardiac mechanism. Ibogaine and noribogaine block hERG potassium channels in cardiomyocytes. Koenig and Hilber (Molecules, 2015) report IC50 values of approximately 4 µM for ibogaine and 3 µM for noribogaine — concentrations reached at therapeutic doses. hERG blockade delays repolarisation, prolonging the QT interval and raising the risk of torsades de pointes, ventricular tachycardia, and cardiac arrest.

Magnitude and outcomes. Case reports document QTc prolongation exceeding 600 ms at therapeutic doses in individuals without pre-existing cardiac disease. A 2026 review in Addiction by Brunt and colleagues characterises the risk as rare but clinically significant. Dozens of deaths have been temporally associated with ibogaine ingestion since 1990.

A 2026 preprint analysing 19,071 patients across 11 clinics reported six deaths within 72 hours, all in opioid use disorder patients. It has not been peer-reviewed, and its authors describe the rate as a lower bound given voluntary participation and unverified self-reported data.

Documented cardiac risk factors include hypokalaemia (present in every fatality case in the Koenig and Hilber review), hypomagnesaemia, concurrent hERG-blocking drugs, CYP2D6 poor-metaboliser status, bradycardia, and structural heart disease.

Psychiatric risks specific to this population. These are where gambling disorder differs from the populations ibogaine has been studied in:

• Bipolar disorder is present in an estimated 18.6% of people with gambling disorder. A 2015 case series in The American Journal on Addictions documented three cases of mania following ibogaine use in individuals with no prior bipolar diagnosis or family history, with grandiose delusions persisting up to two weeks. Bipolar I disorder is a generally accepted contraindication, and a population with near one-in-five prevalence is a poor match for a drug carrying this signal
• Suicide risk is elevated at baseline — roughly 16% lifetime attempt prevalence. A destabilising psychoactive experience without robust psychiatric follow-up is a real hazard
• Dopaminergic stimulation can cause pathological gambling. In the DOMINION study of 3,090 Parkinson's disease patients, impulse control disorders occurred in 14% on any dopaminergic medication and 17% on a dopamine agonist, with compulsive gambling in about 5%. Ibogaine's most-cited mechanism is upregulation of GDNF and dopaminergic function. Whether that helps or aggravates compulsive gambling has never been tested — the direction of effect is genuinely unknown
• Antidepressants, common in this population, raise both serotonergic-interaction and QT-prolongation concerns; off-label antipsychotics add further QT risk

Generally accepted absolute contraindications include known long QT syndrome, structural heart disease, heart failure, recent myocardial infarction, uncorrected electrolyte abnormalities, significant hepatic or renal impairment, pregnancy, active psychosis, and bipolar I disorder.

Legal status. Ibogaine is a Schedule I controlled substance under the U.S. Controlled Substances Act — the most restrictive category, denoting high abuse potential, no currently accepted medical use, and lack of accepted safety under medical supervision. It is not approved for gambling disorder, or any indication, anywhere in the world.

The policy landscape is moving. Texas has committed substantial state funding toward FDA-directed ibogaine clinical trials, and several states have introduced research legislation. But the registered and funded trials target opioid use disorder, co-occurring substance use disorders, PTSD, and traumatic brain injury. Gambling disorder is not on the list.

What would actually advance the question of ibogaine for gambling addiction:

• Preclinical work in gambling-relevant behavioural models. Rodent gambling tasks and probabilistic-discounting paradigms exist and are used to screen candidate compounds. No ibogaine study using them appears in the literature — the single largest gap
• A test of directionality. Given the DOMINION findings, any programme should establish whether ibogaine reduces or increases risk-taking and reward sensitivity before human exposure
• Case reports, honestly published. People are almost certainly already being treated at clinics for gambling problems. Publishing those outcomes — including failures and adverse events — would move the field further than any amount of mechanistic argument
• Durability data. Gambling relapse is driven substantially by environmental cues — app notifications, live-odds advertising, accessible credit — which no pharmacological intervention addresses

The honest bottom line. The case for ibogaine for gambling addiction rests on a hypothesis paper that does not itself address gambling, extrapolation from opioid research into a condition with no physical withdrawal, and a neurobiological profile that may differ from substance addiction in a direction arguing against the approach. Against that sits a documented, potentially fatal cardiac risk and comorbidity-specific contraindications.

CBT, motivational interviewing, opioid antagonists, self-exclusion tools, and financial counselling all have more evidence than ibogaine does here — a low bar, because ibogaine currently has none.

---

This page is educational information, not medical advice. It does not recommend ibogaine or endorse any clinic. If you or someone you care about is struggling with gambling, the National Problem Gambling Helpline is available 24/7 at 1-800-522-4700 (call or text) in the United States. If you are in crisis or having thoughts of suicide, call or text 988 in the U.S. Decisions about treatment should be made with a qualified clinician who knows your full medical and psychiatric history.